“Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3 3b Clinical Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 4, July 2024, p. s404, https://doi.org/10.25251/skin.8.supp.404.